Physalin C

CAS No. 27503-33-9

Physalin C( ——— )

Catalog No. M39121 CAS No. 27503-33-9

Physalin C is a natural product that can be found in physalis angulata. Physalin C shows cytotoxic activities against MCF-7 and HepG2 cells.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 643 In Stock
25MG Get Quote In Stock
50MG Get Quote In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Physalin C
  • Note
    Research use only, not for human use.
  • Brief Description
    Physalin C is a natural product that can be found in physalis angulata. Physalin C shows cytotoxic activities against MCF-7 and HepG2 cells.
  • Description
    Physalin C is a natural product from Physalis alkekengi.
  • In Vitro
    Cell Cytotoxicity Assay Cell Line:MCF-7,HepG2 cells Concentration:0-100 μM Incubation Time:72 h Result:Showed cytotoxic activities with IC50s of 10.5, 24.2 μM for MCF-7,HepG2 cells, respectively.
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    27503-33-9
  • Formula Weight
    510.53
  • Molecular Formula
    C28H30O9
  • Purity
    >98% (HPLC)
  • Solubility
    ———
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Jia-Jia Fan, et al. A Novel Cytotoxic Physalin from Physalis angulata. Natural Product Communications, 2017, 12(10):1589-1591.
molnova catalog
related products
  • Arctigenin

    Arctigenin is a lignan found in certain plants of the Asteraceae;  it has shown antiviral and anticancer effects in glass.

  • Alizurol purple

    Alizurol purple is an agent of biochemical.

  • Magrolimab

    Magrolimab (Hu5F9-G4) is a humanized anti-CD47 IgG4 monoclonal antibody that exhibits antitumor activity by blocking CD47 and binding primarily to the N-terminal pyroglutamate of CD47. It can be used in combination with other compounds for the treatment of recurrent myeloma.